Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415.
Author
Khairnar, Rahul
DeMora, Lyudmila
Sandler, Howard M
Lee, W Robert
Villalonga-Olives, Ester
Mullins, C Daniel
Palumbo, Francis B
Bruner, Deborah W
Shaya, Fadia T
Bentzen, Soren M
Shah, Amit B
Malone, Shawn
Michalski, Jeff M
Dayes, Ian S
Seaward, Samantha A
Albert, Michele
Currey, Adam D
Pisansky, Thomas M
Chen, Yuhchyau
Horwitz, Eric M
DeNittis, Albert S
Feng, Felix
Mishra, Mark V
Journal
JCO Clinical Cancer InformaticsPublisher
American Society of Clinical OncologyType
Article
Metadata
Show full item recordAbstract
Purpose: To compare the predictive ability of mapping algorithms derived using cross-sectional and longitudinal data. Methods: This methodological assessment used data from a randomized controlled noninferiority trial of patients with low-risk prostate cancer, conducted by NRG Oncology (ClinicalTrials.gov identifier: NCT00331773), which examined the efficacy of conventional schedule versus hypofractionated radiation therapy (three-dimensional conformal external beam radiation therapy/IMRT). Health-related quality-of-life data were collected using the Expanded Prostate Cancer Index Composite (EPIC), and health utilities were obtained using EuroQOL-5D-3L (EQ-5D) at baseline and 6, 12, 24, and 60 months postintervention. Mapping algorithms were estimated using ordinary least squares regression models through five-fold cross-validation in baseline cross-sectional data and combined longitudinal data from all assessment periods; random effects specifications were also estimated in longitudinal data. Predictive performance was compared using root mean square error. Longitudinal predictive ability of models obtained using baseline data was examined using mean absolute differences in the reported and predicted utilities. Results: A total of 267 (and 199) patients in the estimation sample had complete EQ-5D and EPIC domain (and subdomain) data at baseline and at all subsequent assessments. Ordinary least squares models using combined data showed better predictive ability (lowest root mean square error) in the validation phase for algorithms with EPIC domain/subdomain data alone, whereas models using baseline data outperformed other specifications in the validation phase when patient covariates were also modeled. The mean absolute differences were lower for models using EPIC subdomain data compared with EPIC domain data and generally decreased as the time of assessment increased. Conclusion: Overall, mapping algorithms obtained using baseline cross-sectional data showed the best predictive performance. Furthermore, these models demonstrated satisfactory longitudinal predictive ability.Identifier to cite or link to this item
http://hdl.handle.net/10713/19327ae974a485f413a2113503eed53cd6c53
10.1200/CCI.21.00188
Scopus Count
Collections
Related articles
- Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
- Authors: Khairnar R, Pugh SL, Sandler HM, Lee WR, Villalonga Olives E, Mullins CD, Palumbo FB, Bruner DW, Shaya FT, Bentzen SM, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Albert M, Currey AD, Pisansky TM, Chen Y, Horwitz EM, DeNittis AS, Feng FY, Mishra MV
- Issue date: 2021
- Obtaining EQ-5D-3L utility index from the health status scale of traditional Chinese medicine (TCM-HSS) based on a mapping study.
- Authors: Wang L, Lu Y, Dai Z, Shi P, Xu J, Chang F, Lu Y
- Issue date: 2022 Dec 15
- Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
- Authors: Davison NJ, Thompson AJ, Turner AJ, Longworth L, McElhone K, Griffiths CEM, Payne K, BADBIR Study Group
- Issue date: 2018 Aug
- Mapping the COPD Assessment Test onto EQ-5D.
- Authors: Hoyle CK, Tabberer M, Brooks J
- Issue date: 2016 Jun
- Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.
- Authors: Skaltsa K, Longworth L, Ivanescu C, Phung D, Holmstrom S
- Issue date: 2014 Mar